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Abstract
BACKGROUND—The American Joint Committee on Cancer’s (AJCC) 7th edition cancer 
staging manual reflects recent changes in cancer care practices. This report assesses changes from 
the AJCC 6th to the AJCC 7th edition stage distributions and the quality of site-specific factors 
(SSFs).
METHODS—Incidence data for renal parenchyma and pelvis and ureter cancers from 18 
Surveillance, Epidemiology, and End Results (SEER) registries were examined, including staging 
trends during 2004–2010, stage distribution changes between the AJCC 6th and 7th editions, and 
SSF completeness for cases diagnosed in 2010.
RESULTS—From 2004 to 2010, the percentage of stage I renal parenchyma cancers increased 
from 50% to 58%, whereas stage IV and unknown stage cases decreased (18% to 15%, and 10% 
to 6%, respectively). During this period, the percentage of stage 0a renal pelvis and ureter cancers 
increased from 21% to 25%, and stage IV and unknown stage tumors decreased (20% to 18%, and 
7% to 5%, respectively). Stage distributions under the AJCC 6th and 7th editions were about the 
same. For renal parenchymal cancers, 71%–90% of cases had known values for 6 required SSFs. 
For renal pelvis and ureter cancers, 74% of cases were coded as known for SSF1 (WHO/ISUP 
grade) and 47% as known for SSF2 (depth of renal parenchymal invasion). SSF values were 
known for larger proportions of cases with reported resections.
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CONCLUSIONS—Stage distributions between the AJCC 6th and 7th editions were similar. SSFs 
were known for more than two-thirds of cases, providing more detail in the SEER database 
relevant to prognosis.
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INTRODUCTION
It has been estimated that there would be 65,150 newly diagnosed kidney parenchyma and 
renal pelvis cancer cases and 2710 cancer cases of the ureter and other urinary organs 
(excluding the urinary bladder) in 2013. In addition, 13,680 and 900 people, respectively, 
were expected to die of these cancers in 2013.1
Incidence rates for kidney and renal pelvis cancers are nearly twice as high among men as 
women. Among men, higher rates occur among American Indian/Alaska Native men (29.0 
per 100,000), with the lowest rates among Asian/Pacific Islander populations (10.1 per 
100,000). Incidence rates among Hispanic, white, and black men lie somewhere in-between 
(19.8, 21.2, and 23.3 per 100,000, respectively).1 Since 1992, incidence rates for these 
malignancies have increased steadily in both men and women, particularly during the past 
decade (2.9% increase per year among men, and 3.1% among women).2 Despite the increase 
in incidence rates, death rates declined during the same period.2 Overall 5-year relative 
survival was about 73%, ranging from 91% for localized to 64% for regional and 11% for 
distant-stage cases. Although 62% of cases were diagnosed with localized stage cancers, 
17% were diagnosed with regional and distant-stage cancers.2
The American Joint Committee on Cancer (AJCC) Staging Manual, 7th edition, was 
published in January 20103 and adopted by the Surveillance, Epidemiology, and End Results 
(SEER) Program registries for cancer cases diagnosed in 2010 and after. Site-specific factors 
(SSFs) were first introduced into the AJCC 7th edition and Collaborative Stage (CS) System 
version 2 (CSv2) schemas for renal parenchymal, renal pelvis, and ureter cancers. 
Understanding these factors has allowed clinicians to better select therapeutic options and 
facilitates stratifying a patient’s risk of progression and evaluating treatment. The objectives 
of this report are to: 1) examine staging trends using the AJCC 6th edition4 during 2004–
2010, 2) compare stage distribution between the AJCC 6th and 7th editions for 2010 cases, 
and 3) assess the completeness of SSFs.
MATERIALS AND METHODS
Analytic Cohort
Data from the November 2012 submission of the SEER-18 registries (and not the Arizona 
Indians or Cherokee Nation registries) were used in this analysis. The SEER-18 registries 
report cancer incidence data to the National Cancer Institute, including demographic 
attributes of patients, stage at diagnosis, and survival time from diagnosis. The SEER-18 
registries (San Francisco [SF]–Oakland standard metropolitan statistical area, Connecticut, 
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Detroit [metropolitan], Hawaii, Iowa, New Mexico, Seattle [Puget Sound], Utah, Atlanta 
[metropolitan], San Jose–Monterey [SJM], Los Angeles, Alaska Natives, rural Georgia, 
California excluding SF/SJM/Los Angeles, Kentucky, Louisiana, New Jersey, greater 
Georgia) cover 28% of the United States population. Analytic cohorts included in this report 
used similar exclusion criteria for cancers of 1) the renal parenchyma (International 
Classification of Diseases for Oncology, 3rd edition [ICD-O-3]5 topographic code: C64.9) 
and 2) renal pelvis (C65.9) and ureter (C66.9) (Table 1). Invasive renal parenchyma and 
both in situ and invasive renal pelvis cancer cases diagnosed in 2010 were included for the 
comparison of stage distribution between the AJCC 6th and 7th editions. The AJCC 7th 
edition schemas for these sites include identical ICD-O-3 histological types: 8000–8576, 
8940–8950, 8980–8981. Autopsy- and death certificate–only cases were excluded, as were 
cases with histologies that were not included in the AJCC 6th and 7th editions. For the 
purpose of evaluating the completeness and quality of SSFs, only invasive cases diagnosed 
in 2010 were included.
Key Changes in AJCC Staging Between the 6th and 7th Editions
AJCC staging is based on detailed information regarding tumor size (T), the extent of lymph 
node involvement (N), and metastasis (M). Changes in the AJCC 7th edition3 for renal 
parenchymal tumors divided T2 (tumor >7 cm in greatest dimension, limited to the kidney) 
into T2a (tumor size >7 but ≤10 cm, limited to the kidney) and T2b (tumor size >10 cm, 
limited to the kidney). Furthermore, ipsilateral (same side) adrenal gland involvement was 
reclassified as T4 if there was contiguous invasion and as M1 if invasion was not 
contiguous; renal vein involvement was reclassified as T3a from T3b; and nodal 
involvement was simplified to N0 versus N1, without distinguishing metastasis in a single 
regional lymph node from metastasis in more than 1 regional lymph node as in the AJCC 
6th edition. Since the publication of the AJCC 6th edition, new evidence supported the 
division of T2 tumors and reclassification of the T3a and N categories. The rationale for 
dividing T2 into T2a and T2b is based on large, retrospective cohort studies6–10 with 
extended follow-up that demonstrate substantially different outcomes for these subgroups. 
Furthermore, multiple studies11–18 have documented a poor prognosis for patients with 
ipsilateral adrenal involvement similar to patients with T4 or M1 disease; these tumors are 
now reclassified to reflect current concepts about likely mechanisms of spread. In addition, 
tumors with isolated renal vein thrombus are known to have a relatively favorable 
prognosis19,20 and are now staged as T3a rather than T3b. Last, nodal involvement is now 
consolidated as N1 because most studies21–24 suggest a relatively poor prognosis among 
patients with nodal involvement. For renal pelvis and ureter cancers, the definition of TNM 
and the stage grouping have not changed from the AJCC 6th edition.
Summary of SSFs
Renal parenchyma—SSFs for renal parenchyma include invasion beyond capsule 
(SSF1), vein involvement (SSF2), ipsilateral adrenal gland involvement (SSF3), 
sarcomatoid features (SSF4), Fuhrman nuclear grade (SSF6), and extranodal extension of 
regional lymph nodes (SSF8). Collection of SSF5 (histologic tumor necrosis) and SSF7 (size 
of metastasis in lymph nodes) was never required by the SEER Program, but they were 
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voluntarily reported to SEER in some instances, primarily by Commission on Cancer–
accredited facilities.25
The kidney is encased by a fibrous capsule and surrounded by perirenal fat. Information 
about invasion beyond the capsule and involvement of the ipsilateral adrenal gland and/or 
vein has been collected in the CS extension field. The CS extension field identifies the 
primary tumor growth within the organ or its extension into neighboring organs. In CSv2, 3 
SSFs were added to more specifically define tumor extension. SSF1, invasion beyond 
capsule, provides the specific depth of tumor extension outside the kidney capsule. SSF2 
(vein involvement) records the presence and level of involvement of specific major named 
blood vessels. Although contiguous and noncontiguous ipsilateral adrenal gland 
involvement is collected in the CS extension and in the CS metastasis at diagnosis field, 
SSF3 (ipsilateral adrenal gland involvement) provides detailed information about adrenal 
gland involvement.26
The other 3 SSFs affect prognosis. SSF4, sarcomatoid features, documents any sarcomatoid 
or spindle cell features in any renal cell carcinoma. Patients with renal cell carcinoma with 
sarcomatoid differentiation tend to have worse outcomes than renal cell carcinoma without 
sarcomatoid differentiation.27,28 Fuhrman nuclear grade, SSF6, is a 4-grade system based on 
nuclear diameter and shape and the prominence of nucleoli in the tumor cells. Patients with 
higher grades had worse survival rates.29 The definitions of nuclear grade are documented in 
the kidney cancer protocol of the College of American Pathologists checklist30: G1, nuclei 
round, uniform, approximately 10 μm, nucleoli inconspicuous or absent; G2, nuclei slightly 
irregular, approximately 15 μm, nucleoli evident; G3, nuclei very irregular, approximately 
20 μm, nucleoli large and prominent, G4, nuclei bizarre and multilobated, 20 μm or greater, 
nucleoli prominent, chromatin clumped.
SSF8, extranodal extension of regional lymph nodes, is defined as a metastatic tumor 
growing from within the lymph node outward through the lymph node capsule and into 
surrounding connective tissues. Extranodal extension can be detected clinically, on gross 
examination of dissected lymph nodes, or microscopically. Kidney cancer patients with 
extranodal extension have a worse prognosis than those without nodal involvement.
Renal pelvis and ureter—Kidney and renal pelvis cancers often are combined for the 
purposes of cancer surveillance, with ureter cancer presented separately. Renal pelvis and 
ureter cancers share CSv2 SSFs, however, and are grouped in the AJCC stage coding 
schema; cancers of the renal parenchyma have a different set of SSFs.3 Findings for both 
renal pelvis and ureter cancers are presented in this report.
The SSFs for these cancer sites are World Health Organization or International Society of 
Urological Pathology (WHO/ISUP) grade31 (SSF1) and depth of renal parenchymal 
invasion (SSF2).32 Both SSFs for these sites affect prognosis. SSF1 for renal pelvis and 
ureter is the WHO/ISUP grade, a 2-grade system (low and high grade). This grading system 
was proposed by ISUP in 1998 and adopted by WHO in 2004 to better classify the tumor 
grade for urothelial carcinomas of the renal pelvis, ureter, bladder, and urethra.33,34 The 
strengths of the WHO/ISUP grade’s clear-cut criteria and the elimination of subjective and 
Altekruse et al. Page 4













arbitrary interpretation have greatly improved the ambiguous language that marked the 1973 
WHO system.35 SSF2, depth of renal parenchymal invasion, records the depth of tumor 
invasion into the renal parenchyma in millimeters as documented in the pathology report.
Data Analysis
AJCC 6th edition stage distribution was examined by year of diagnosis from 2004 through 
2010. The annual percent change (APC) in frequencies by stage and corresponding 95% 
confidence intervals (CIs) were calculated. Database queries were performed with 
SEER*Stat v 8.0.2 (IMS, Calverton, MD).
A Kappa statistic36 was used to measure staging agreement between the AJCC 6th and 7th 
editions for renal parenchyma and renal pelvis and ureter cancers (Proc Freq Agree option 
and Test Kappa command; SAS v 9.2 Cary, NC). Frequencies and percentage distribution of 
SSFs by known, unknown, and not applicable categories were computed, including analyses 




A total of 79,908 renal parenchymal cancer cases and 11,611 renal pelvis and ureter cases 
diagnosed during 2004–2010 were available for analysis in examining staging trends based 
on the AJCC 6th edition. For comparing AJCC 6th and 7th edition stage distributions, the 
analytic data sets included 12,218 invasive and in situ renal parenchymal cancer cases and 
1684 invasive and in situ renal pelvis and ureter cancer cases diagnosed during 2010 (Table 
1). Analyses of SSFs included only invasive cancer, yielding 12,203 renal parenchymal 
cancer cases and 1193 renal pelvis and ureter cancer cases diagnosed in 2010.
AJCC 6th Edition Stage Distribution Trends
The percentage of stage I renal parenchymal cancer cases increased from 50% in 2004 to 
58% in 2010 (APC, 6.9%; 95% CI, 3.8% to 10.0%; Fig. 1A). Statistically significant 
increases were also seen in the number of stage II cases (APC, 2.6%; 95% CI, 0.3% to 
5.0%) and in stage III cases (APC, 3.6%; 95% CI, 2.4% to 4.9%). Although not statistically 
significant, from 2004 to 2010, the percentage of tumors classified as stage IV decreased 
from 18% to 15%, and the percentage designated as unknown stage decreased from 10% to 
6%.
For renal pelvis and ureter cancer but not renal parenchymal cancer, stage designations 
included 0a and 0is (Fig 1B). The percentage of cases that were diagnosed at stage 0a 
increased to 25% in 2010, surpassing case counts for all other stages (APC, 3.8%; 95% CI, 
0.6% to 7.0%). Stage 0a, or abnormal cells, differs from stage 0is, or carcinoma in situ. 
Among other stages, only the increase in counts of stage III tumors was significant (APC, 
3.4%; 95% CI, 0.7% to 6.3%). Stage III and IV tumors accounted for between 15% and 20% 
of cases throughout the surveillance period, and stage II tumors accounted for fewer than 
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10% of cases in 2009 and 2010. Unknown and 0is stage tumors both accounted for fewer 
than 5% of cases in 2010.
Comparison of Stage Distributions
The impact of changes in definitions between the AJCC 6th and 7th editions for cancers of 
the renal parenchyma diagnosed during 2010 is shown in Table 2. For renal parenchymal 
cancers, slightly more cases were classified as stage I under the 7th edition guidelines than 
under the 6th (58.6% versus 58.3%) and as stage III (13.6% versus 13.1%). Fewer cases 
were classified as unknown stage (5.0% versus 5.6%). Differences in other staging 
categories were even more modest. With respect to renal pelvis and ureter tumors, only 3 
tumors were reclassified—all from an unknown stage under the AJCC 6th edition to stage I 
under the 7th edition.
Table 3 provides a more detailed cross-tabulation of AJCC 6th and 7th edition staging for 
cancers of the renal parenchyma and renal pelvis and ureter diagnosed during 2010. Almost 
perfect agreement was seen for both cancer sites (Kappa, 0.98 and 0.99, respectively). Some 
discordance was observed, however. For renal parenchymal tumors, 75 of 690 cases (11%) 
classified as unknown stage under the AJCC 6th edition guidelines were reassigned to 
specified stages under the 7th edition. In addition, 41 of 1805 cases (2%) classified as stage 
IV under the AJCC 6th edition were reclassified to stage III under the 7th edition. Of 1684 
cases with renal pelvis and ureter cancers, 1681 (99.99%) had identical stage classifications 
under both the AJCC 6th and 7th editions.
Completeness of SSFs
A summary of codes corresponding with not applicable, known, and unknown values for 
SSFs is presented in Table 4. Fewer than 1% of renal parenchymal cancers were reported as 
not applicable. Known responses ranged from a low of 70.5% for SSF6 (Fuhrman nuclear 
grade) to a high of 90.3% for SSF8 (extranodal extension). Data present beyond the known, 
unknown, and not applicable levels are not shown in Table 4.
Renal parenchyma—Among the 12,203 renal parenchymal cancer cases, 9426 cases 
(77.2%) had known values for invasion beyond capsule (SSF1; Table 4). This includes 8068 
cases (66.1%) with no reported invasion beyond the capsule and 1358 (13.8%) with reported 
capsular invasion. Of these 1358 cases, 1307 (96.2%) had detailed information on the extent 
of invasion, and 51 (3.7%) had invasion beyond the capsule that was not otherwise specified 
(NOS). Of the 1307 cases with detailed information on invasion, 807 cases had lateral 
invasion, 311 had medial invasion, and 189 had both lateral and medial invasion. Among 
2777 cases (22.8%) without data on invasion beyond the capsule, 2212 (79.7%) did not have 
a surgical resection. Among cases with reported resections, large proportions had known 
SSF values, ranging from 87.2% for SSF 6 to 96.7% for SSF 2 (Table 5). Information on 
vein involvement (SSF2) was available for 9586 cases (78.6%) and missing for 2617 
(21.4%) of the 12,203 cases. Of the 9586 cases with information, 8573 (89.4%) did not 
present with vein involvement, and 1013 (10.6%) had reported vein involvement. The 
majority of these cases (81%) did not receive a surgical resection.
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Ipsilateral adrenal gland involvement (SSF3) data were reported for 9932 cases (81.4%); 
18.6% of cases had no relevant information. Among cases with data, 9679 (97%) did not 
present with ipsilateral adrenal gland involvement, 184 (1.9%) had contiguous or 
noncontiguous involvement, and 69 (0.69%) had unknown contiguous/noncontiguous 
involvement.
Known sarcomatoid features (SSF4) data were available for 9624 cases (78.8%), with data 
unknown results for 2579 cases (21.2%). Among cases with information, 9252 (96.2%) did 
not present with sarcomatoid features; 359 (3.7%) did present with these features. The 
majority of the cases with unknown values (65%) had no pathologic examination of the 
primary site. This variable was not applicable to 13 cases (0.1%) without renal cell 
carcinoma morphology.
Fuhrman nuclear grade (SSF6) was known for 8607 cases (70.5%). Of these, 1030 (12%) 
were grade 1 cases, 4525 (52.6%) were grade 2 cases, and 2436 (28.3%) were grade 3 cases, 
with the remaining 616 (7.2%) being grade 4 cases. Another 3527 cases (29%) were missing 
this information, including 1675 (13.7%) that did not have a histologic examination. The 
remaining 69 cases (0.57%) did not have renal cell carcinoma morphologies.
Extranodal extension of regional lymph nodes (SSF8) was known for 11,015 cases (90.3%). 
The SSF8 value was unknown for 1188 cases (9.7%). There were no cases with missing or 
blank values for this data item.
Renal pelvis and ureter—Among renal pelvis and ureter cancers, 73.3% had known 
values, including 61.3% high-grade urothelial carcinomas and 12% low-grade urothelial 
carcinomas. Another 1.3% of WHO/ISUP grade (SSF1) responses were reported as not 
applicable, and the remaining 25.4% were unknown. The majority of responses for depth of 
renal parenchymal invasion (SSF2; 53.1%) were unknown. All remaining responses (46.9%) 
were listed as known. Among the known responses, 549 of 560 (98%) had no parenchymal 
invasion present/identified. When analysis was restricted to cases with reported resections, 
the majority had known SSF values, ranging from 57.5% for SSF 2 to 84.7% for SSF 1 
(Table 5).
Quality assessment, renal parenchyma—For quality control purposes, cross-
tabulations of SSFs and existing SEER variables were performed when possible (data not 
shown). For renal parenchyma SSF1 (invasion beyond the capsule), results were consistent 
with those for CS-extension-confirmed invasion. Cases with T3a and more advanced stage 
tumors (invasion beyond the capsule) generally had invasive cancer. Similarly, comparisons 
of Fuhrman nuclear grade (SSF6) and ICD-O grade/differentiation code revealed a high 
level of agreement among cases with known grade. When compared with existing staging 
variables, inconsistencies were seen for SSFs 2, 3, and 8, which remain the subjects of 
investigation.
Quality assessment, renal pelvis and ureter—Cross-tabulations for renal pelvis and 
ureter WHO/ISUP grade (SSF1) and ICD-O grade/differentiation code also showed 
agreement among cases with known grade.
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Stage distributions under the AJCC 6th and 7th editions were similar. As previously 
reported,37 the annual increase in stage I cases explains the overall increase in renal 
parenchyma cancer incidence rates. Of the 6 renal parenchyma and 2 renal pelvis and ureter 
SSFs that currently are collected by the SEER Program, 4 were considered ready for release 
based on completeness, consistency of results compared with existing and closely related 
variables, and the insight they provide into staging and prognosis. This includes 3 SSFs for 
renal parenchymal cancer: SSF1 (invasion beyond capsule), SSF4 (sarcomatoid features), 
and SSF6 (Fuhrman nuclear grade). Of these, sarcomatoid differentiation and Fuhrman 
nuclear grade have particular prognostic value; invasion beyond the capsule is an anatomic 
field that largely duplicates existing staging data items. Although both renal pelvis and 
ureter cancer SSFs have prognostic value, only SSF1 (WHO/ISUP grade) was recommended 
for release, given the partial completeness of SSF2 (renal parenchymal invasion) data. For 
an SSF to be retained in the SEER data collection, not only does the SSF need to have a high 
degree of completeness, but the known value should provide added insight, such as enabling 
classification of patients into refined and specific categories for projecting prognosis and 
recurrence and guiding treatment options.
For kidney parenchyma, there are 6 SSFs. Invasion beyond capsule (SSF1) is included in 
both the AJCC 6th and 7th editions and has been shown to be prognostic. SSF1 captures the 
anatomic location of invasion beyond the capsule such as lateral invasion to perinephric fat 
or medial invasion to the renal sinus. Invasion beyond the capsule corresponds to a 
pathologic T stage designation of at least T3 and T4 if invading adjacent organs. Collection 
of SSF1 in addition to staging under the AJCC 6th or 7th edition added new and prognostic 
information on the anatomic location of invasion for 1307 of 1358 cases (96%) with 
reported invasion beyond the capsule. Vein involvement (SSF2) is somewhat redundant 
because it is a component of the AJCC 7th edition staging system, which updates the AJCC 
6th edition to reflect the prognostic implications of various levels of vein involvement.38 
Cases are assigned into 3 categories: T3a (renal vein only), T3b (inferior vena cava [IVC] or 
IVC below the diaphragm), and T3c (IVC above the diaphragm). Interest in ipsilateral 
adrenal involvement (SSF3) reflects awareness that outcomes for patients with adrenal gland 
invasion are significantly worse than for patients with extension of carcinoma only into the 
perinephric adipose tissue,11 and prompted the change in the AJCC 7th edition classification 
for adrenal involvement in renal cell carcinoma. Tumors with direct extension through the 
kidney into the adrenal gland are T4 lesions, and tumors with ipsilateral adrenal metastasis 
not secondary to direct extension are categorized as M1 lesions. With the updates in the 
AJCC 7th edition, SSF3 is redundant and adds no additional prognostic information.
Unlike SSFs 1, 2, and 3, the presence of sarcomatoid features (SSF4) and Fuhrman nuclear 
grade (SSF6) are anatomic-independent prognostic factors. Both these SSFs are of 
considerable clinical value.39,40 Although initially validated as a prognostic factor in clear 
cell renal cell carcinoma, contemporary studies have shown the prognostic value of nuclear 
grading in both clear cell and papillary renal cell carcinoma.41 Although a higher nuclear 
grade and the presence of sarcomatoid features are associated with a more advanced T stage, 
these factors are independently associated with outcomes among cases matched by stage. 
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For these reasons, SSFs 4 and 6 are the most clinically useful and validated SSFs for kidney 
parenchymal tumors.
With respect to renal pelvis and ureter cancer, a high WHO/ISUP grade (SSF1) is 
independently associated with worse outcomes in surgical cases.42 WHO/ISUP grade was 
known for 85% of cases with resection. SSF2 (depth of renal parenchymal invasion as a 
marker of recurrence) also has been validated43; however, most values for this variable were 
unknown. Additional SSFs for renal pelvis and ureter cancer might be considered based on 
prognostic value. Promising markers for these understudied cancers include tumor 
architecture,44,45 multifocality,46 and the presence of concomitant carcinoma in situ.47 In 
some studies,48 tumor location (ie, ureter, renal pelvis, or both) has also been suggested to 
have prognostic value.
Alternative approaches to efficiently collecting new SSFs may have merit, including the use 
of pilot studies to assure the feasibility of recording promising biomarkers.49 The AJCC 7th 
edition CS manual incorporated enhanced registry data standards including nonanatomic 
prognostic factors to provide evidence-based staging. The 4 SSFs that were recommended to 
be added to the SEER public use research database by its internal data release committee 
based on considerations such as completeness and inherent value include all 3 nonanatomic 
SSFs. These are renal parenchymal cancer SSF4 (sarcomatoid features), SSF6 (Fuhrman 
nuclear grade), and renal pelvis and ureter SSF1 (WHO/ISUP grade). The AJCC 7th edition 
schema was intended to leverage rapidly increasing specific knowledge of cancer biology 
and electronic data capture technology, with the goal of supporting personalized cancer care 
through outcome prediction models.3 Long-term follow-up of survival may demonstrate the 
prognostic value of the AJCC 7th edition SSFs. The assessment may also reveal synergies 
between SSFs that affect prognosis.
This study has both strengths and limitations. At the time of its publication, the AJCC 7th 
edition staging manual reflected a consensus understanding of cancer staging. Adopting the 
major revisions included in the AJCC 7th edition staging manual as a central part of 
registry-based cancer surveillance was an expansion of concepts included in the AJCC 6th 
edition. The introduction of multiple SSFs was intended to refine stage classification and 
provide insight into prognosis and treatment decisions. Limitations include the cost of this 
endeavor and inconsistencies between SSF results compared with existing and related 
variables. A potential bias was introduced by the incompleteness of some SSFs, as 
demonstrated by results of modeling to impute missing values of progesterone and estrogen 
receptor status in breast cancer cases.50
In summary, results from this study suggest that changes in definitions between the AJCC 
6th and 7th editions do not significantly affect stage distribution. Furthermore, it appears 
feasible to collect select SSFs for renal and ureter cancers within the SEER registries. Long-
term follow-up of survival may confirm the prognostic value of these variables. Alternative 
strategies for the inclusion of proposed SSFs in programmatic SEER registry operations may 
include pilot studies of promising biomarkers so that informed decisions about the efficiency 
and value of future data collections may be made.
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Stage distribution trends for (A) renal parenchymal cancer and (B) renal pelvis and ureter 
cancer. Data from SEER registries during 2004–2010, AJCC 6th edition.
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TABLE 1
Exclusion Criteria for Renal Parenchyma and Renal Pelvis and Ureter Cancer Analytic Cohorts, SEER, 2010
Exclusion Criteria AJCC 6th & 7th Stage Cohort SSF Cohort
A. Renal parenchymaa
 In situ cases Yesa Yes
 Autopsy- or death certificate–only cases Yes Yes
 Histologies for which AJCC 6th Yes Yes
 & 7th stage not defined
 Code 988, blank for each SSF No Yes
 Arizona Indians and Cherokee Yes Yes
 Final sample size 12,218 12,203
B. Renal pelvis and ureter
 In situ cases No Yes
 Autopsy or death certificate only cases Yes Yes
 Histologies for which AJCC 6th and 7th stage not defined Yes Yes
 Code 988, blank for each SSF No Yes
 Arizona Indians and Cherokee Yes Yes
 Final sample size 1684 1193
Abbreviations: AJCC, American Joint Committee on Cancer; SEER, Surveillance, Epidemiology, and End Results; SSF, site-specific factor.
a
Papillary noninvasive carcinoma (0a) and in situ (0is) not applicable to renal parenchyma
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TABLE 2




AJCC 6th AJCC 7th
n % n %
I 7127 58.3 7156 58.6
II 995 8.1 1004 8.2
III 1601 13.1 1658 13.6
IV 1805 14.8 1784 14.6
Unknown 690 5.6 616 5.0
Total 12,218 100.0 12,218 100.0
B. Renal Pelvis and Ureter
Stage
AJCC 6th AJCC 7th
n % n %
0a 416 24.7 416 24.7
0is 75 4.5 75 4.5
I 347 20.6 350 20.8
II 143 8.5 143 8.5
III 323 19.2 323 19.2
IV 303 18.0 303 18.0
Unknown 77 4.6 74 4.4
Total 1684 100.0 1684 100.0
Abbreviations: AJCC, American Joint Committee on Cancer; SEER, Surveillance, Epidemiology, and End Results.
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